A pair of Swedish women have developed a remarkable solution for safety helmets: The Invisible Bike Helmet.
Tired of strapping ugly, uncomfortable styrofoam-and-plastic turtle shells to their heads, the pair came up with a revolutionary solution that does manage to give you full head protection without, remarkably, wearing anything on your head.
There’s also a new Inflatable Helmet. The airbag helmet is worn around the neck like a scarf or collar. The collar contains a folded up airbag that inflates in the event of an accident.
Sensors within the collar pick up strange or sudden movements. The airbag is shaped like a hood. It surrounds and protects the user’s head. (Natalie Portman wore one because of her character’s epilepsy in the movie Garden State!)
Then, of course, there’s lots more out there to choose from. And you can create your own personalized design…
What if you could predict an oncoming seizure in time for you stop it? Or even prevent it? That day may be coming sooner than you think, thanks to these seven new technologies.
You’ll learn what they are, how they work and how far along they are.
There’s a lot of new and exciting research going on — all over the world – about predicting and preventing seizures. The latest research combines scientists who excel in engineering, math, physics and technology in a dedicated collaborative effort.
And even though most the actual technology isn’t here yet, the future holds promise for us all.
Deep Brain Stimulation
One seizure-interrupting device, called a responsive neurostimulator system, is for patients with temporal lobe epilepsy, bi-temporal epilepsy, and neocortical epilepsy.
This therapy uses a pacemaker-like device, implanted in the brain to deliver a small amount of electricity when it detects the onset of a seizure.
Approximately 30,000 people worldwide are currently using deep brain stimulation (DBS) to treat neurological or psychological conditions. And DBS is only the beginning.
Aryeh Taub of Tel Aviv University’s School of Psychological Sciences believes that, in the future, an interface with the ability to restore behavioral or motor function, lost due to tissue damage is achievable — especially with the help of their new electrode coating.
“We duplicate the function of brain tissue onto a silicon chip and transfer it back to the brain,” Taub says, explaining that the electrodes will pick up brain waves and transfer these directly to the chip.
“The chip then does the computation that would have been done in the damaged tissue, and feeds the information back into the brain — prompting functions that would have otherwise gotten lost.”
The theory is that direct electrical stimulation of the brain can prevent or decrease seizure activity.
However, several fundamental questions remain to be resolved. They include where in the brain the stimulus should be delivered and what type of stimulation would be most effective.
One goal of this research is to combine the beneficial aspects of electrical stimulation with seizure detection technology, in an implantable responsive stimulator.
The device would detect the onset of a seizure and deliver an electrical stimulus that would safely block seizure activity, without interfering with normal brain function.
The device works by combing three components:
A lead, composed of a thin wire with electrode contacts on it, is implanted surgically into the brain. (Sometimes only one side of the brain is treated, and other times two brain leads are implanted, one on the right side and one on the left.)
A pacemaker-like generator, which is placed under the skin in the chest region, and is programmed to deliver the electrical stimulation to the brain lead.
A connecting cable, tunneled under the scalp and neck, which links the brain lead to the generator.
A programming computer, which allows the doctor to adjust the stimulation intensity and rate, along with other settings from outside the body. Settings are adjusted to maximize benefit and minimize any side-effects related to the stimulation.
Overall, researchers say more than half of those treated experienced a reduction in epileptic seizures of at least 50 per cent.
However, even though the effectiveness of this new treatment focuses on those with drug-resistant epilepsy, the treatment will not be suitable for all patients with epilepsy.
One seizure-interrupting device, called a responsive neurostimulator system, is now being tested in a multicenter clinical trial of people with temporal lobe epilepsy, bi-temporal epilepsy, and neocortical epilepsy.
This therapy uses a pacemaker-like device implanted in the brain to deliver a small amount of electricity when it detects the onset of a seizure.
New research adds hope that those with epilepsy could one day wear tiny brain sensors that detect an impending seizure, and release medicine from implanted pumps in time to avert an attack.
The researchers, based at the Pitie-Salpetriere Hospital in Paris, measured changes in the electrical activity of the brains of 23 people with epilepsy using an EEG, (standard scalp electroencephalograph), a machine used routinely in the diagnosis and management of the disease.
They then used highly sophisticated mathematics to translate those recordings into tracings that show spikes in the pattern of electrical activity.
“What this does is suggest there may be another role for the standard EEG. Eventually, this might be miniaturized and implanted, like a pacemaker,” Dr. Timothy Pedley of Columbia Presbyterian Medical Center in New York, said.
“The skull, spinal fluid and tissue on the scalp dampens the signals by about 50 or 100 times,” Pedley said. “Until this study, no one knew it was possible to do it on the scalp with a standard EEG.”
The scientists made recordings from the scalp and, to test the accuracy of the scalp analyses, also recorded activity from inside the brain. The changes noted by the two methods corresponded well, the study said. In fact, the machines detected oncoming seizures in 25 of the scalp recordings.
The discovery of gene mutations that cause specific epilepsy syndromes, has led to the possibility of using gene therapy to counter the effects of these mutations. In gene therapy, researchers typically introduce new genes into brain cells.
Viruses can also be used to introduce genes for proteins such as GABA into non-neuronal cells. These cells are then transplanted into the brain to act as “factories” to produce potentially therapeutic proteins.
One advantage of gene therapy is that it can alter the cells in just one part of the brain. Researchers can control the activity of the introduced genes by using a genetic “switch” that responds to antibiotics or other chemicals.
This allows doctors to turn the gene therapy off if it causes intolerable side-effects or other problems. Theoretically, this type of therapy should last longer and cause fewer side-effects than medication.
Also, researchers are working to identify more gene variations and to understand how they influence individual responses to treatment.
Eventually, it may become possible to test for these genetic variations and, to use the information to prescribe more effective treatments. Researchers also may be able to develop ways of overcoming genetic resistance to treatment.
“What effect a compound is going to have partly depends on where in the seizure circuit that new compound or gene is being placed. You could put the same chemical in two places and get two different results,” said Dr. Edward Bertram III, a professor of neurology at the University of Virginia.
“That is going to be the issue as they try to develop this: Where should we be putting this to have the best effect? On the promising side, they put (the gene) in a restricted area and had an effect. That is a great first step.”
Another emerging approach for treating epilepsy is cell transplantation. Researchers can transplant either mature cells or stem cells derived from fetal tissue.
Cells used for transplant are sometimes genetically engineered to produce substances to reduce seizures, or protect neurons from damage.
Cell transplantation therapies for epilepsy are still in preliminary stages of development. However, the encouraging results of animal studies suggest that this type of therapy may eventually be used to treat drug-resistant human epilepsy.
In about 50 percent to 70 percent of epilepsy cases, an underlying cause of seizures cannot be determined. But in recent years, advances in genetics, biochemistry and functional imaging have helped researchers identify the biological basis of some forms of the disease.
The lab team of Scott C. Baraban, PhD, a key scientist at the UCSF is working with mice that possess the same genetic, biochemical and anatomical defects that are seen in specific types of human epilepsy.
“The cells actually make new synapses,” says Baraban. “That’s the key feature. By making a new synapse with host cells, a transplanted cell acts more like a native cell. We’re basically rewiring the brain.”
It takes about a month for transplanted cells to spread out from the site of transplantation, settle down at their new neural addresses, grow up and connect with their neighbors.
Baraban and his colleagues have also begun working with human stem cells in a project funded by the California Institute for Regenerative Medicine. The aim is to develop a treatment, based on using cell transplantation, to boost inhibitory circuits in the brain.
While the strategy appears quite promising so far, there is plenty of additional pre-clinical work to do before any human clinical trials begin.
Previous clinical and experimental observations have demonstrated that gentle cooling of the brain to 20 degrees celsius is capable of markedly reducing subsequent seizure frequency and intensity in focal seizures. And even terminate them.
Researchers at University of Chicago’s Argonne National Laboratory have developed the first automated system that can both reliably predict epileptic seizures in advance of clinical onset, and induce local hypothermia to the affected brain region quickly enough to suppress the seizures.
This ground-breaking technology consists of miniature brain implants for automatic prediction and control of seizures in humans, with a small external unit for monitoring both patient and system.
The detection device is a surface acoustic wave probe implant, which measures local changes in the brain temperature as a predictor of epileptic neuron activity.
The cooling component consists of an array of probes, implanted in the brain as a means of rapidly cooling the epileptic zone to suppress seizures.
The cooling device and sensor electronics are mounted on the head; a small telemetry system worn around the waist measures the sensor readings and triggers the cooling device.
The Argonne-developed system has the potential to revolutionize the treatment of epilepsy and improve the quality of life for thousands of epilepsy patients who, thus far, have been debilitated by seizures.
The system is expected to help patients lead more normal lives, operate motor vehicles and machinery, and hold jobs that require continuous alertness.
In recent years, researchers have begun to develop immune-modulating therapies, or vaccines, to treat neurological disorders. This type of therapy employs the immune system to disable proteins contributing to disease. Investigators are now beginning to test immune therapies specifically for epilepsy.
For example, in one study of an experimental vaccine for epilepsy, researchers used an AAV (adeno-associated virus) vaccine to generate antibodies that blocked a sub-unit of the NMDA receptor. NMDA receptors are one kind of receptor for the excitatory neurotransmitter glutamate; previous studies have shown that they contribute to the neuronal injury associated with epilepsy.
The vaccine in this study helped to prevent seizures in a rat model of temporal lobe epilepsy.
And researchers at Jefferson Medical College have developed an oral vaccine that protects rats’ brains from stroke and prevents seizures. Eventually, such a vaccine may be used for epilepsy. The oral vaccine causes the body to develop antibodies that recognize a protein in the brain.
Because of the brain’s blood-brain barrier, the vaccine causes no impairment of a rats animals’ behavior, says, Matthew During, MD, professor of neurosurgery at Jefferson, who led the work. “It protects them significantly from subsequent insults such as an epileptic seizure or a stroke for at least five months after a single oral dose.”
“It’s been difficult to develop good drugs because when they get across the blood-brain barrier, they don’t function very well and don’t have much selectivity,” Dr. During says.
“A major problem in treating many neurological diseases is not so much the target, but those drugs which cross the blood-brain barrier tend to affect and alter the function of all the brain, not just the area where the problem lies.”
“Here with our vaccine approach, the antibodies don’t get across the barrier efficiently,” he says. “However, with epilepsy, the increased brain activity allows the antibodies to cross the barrier more readily.”
“If the antibodies get across the barrier, bind to and antagonize the receptor specifically in the injured brain region, animals will behave perfectly normal and you’ve protected against the epileptic seizure.”
The relatively young field of neuroengineering uses engineering technology, to investigate and treat neurological diseases.
Using the electrochemical properties of neurons as a foundation, neuroengineers seek to monitor and modulate abnormal brain function, using several novel — and often nonpharmacological — methods.
These new implantable antiepileptic devices, currently under development and in pivotal clinical trials, hold great promise for improving the quality of life for millions of people with epileptic seizures in the future.
A broad range of strategies is currently being investigated, using various modes of control and intervention in an attempt to stop seizures.
The initial results are exciting, but considerable development and controlled clinical trials will be required before these treatments become accepted for clinical care.
For example, investigators are also working to develop a high-quality, complete archive of intracranial EEG data, symptoms, brain images, and other information to help researchers understand how to predict and interrupt seizures. They are developing improved batteries, electrode arrays, and brain-computer interfaces.
NeuroVista has developed an implantable device system that continuously collects and analyzes EEG data to detect impending seizures.
The system uses an external patient-carried device with a very simple interface — three colored lights — to indicate the risk of an impending seizure. It’s currently undergoing study human clinical trials in Australia.
The hope is to use this technology to guide the administration of fast-acting drugs to prevent seizures.
Other research adds hope that people with epilepsy could one day wear tiny brain sensors that detect an impending seizure and, release medicine from implanted pumps in time to avert an attack.
And Danish scientists have found a physiological way to predict a seizure. By measuring the heart rate variability of patients with epilepsy, they have constructed a wireless epilepsy alarm, which is easier and less dangerous to implant in patients.
“It’s much less complicated to construct a wireless sensor which can be attached to a patient’s heart than constructing a sensor for the brain,” says Jesper Jeppesen, leader of the project.
The researchers estimate that a wireless epilepsy alarm will be developed in approximately 5-10 years, since the method has to be tested over a longer period of time on patients with different types of epilepsy.
The field of seizure prediction, in which engineering technologies are used to decode brain signals and search for precursors of impending epileptic seizures, holds great promise to elucidate the dynamical mechanisms underlying the disorder, as well as to enable implantable devices to intervene in time to treat epilepsy.
Much of this research uses computational neuroscience, which involves both measuring and extracting quantitative features from neurophysiological data, in order to localize, decode and predict the behavior of a system.
By using mathematical models of neural function, investigators can test diagnostic and therapeutic technologies robustly before implementation in humans.
Such computer models are particularly powerful because they can simulate neurological function on multiple scales simultaneously, ranging from individual ion channels and single cell function, through local networks of neurons,to complete systems.
The evolution of engineering technology as applied to epilepsy presents renewed promise to potentially identify periods of time when the probability of seizure onset is increased, and to deliver responsive therapy to prevent epileptic events from occurring.
Many investigators feel that it is likely that seizure detection and prediction methods will be improved if they are tuned to each individual patient. It is also likely that as the network dynamics and high-frequency data are further understood, new methods of seizure prediction will be discovered.
It’s a brave new world out there. And although these detecting devices are just at the testing stage, in time, perhaps this new technology will be used to predict, interrupt or even prevent a seizure.
Individually, they present so many possibilities. And together, they represent hope for all of us in the future.
To subscribe to Epilepsytalk.com and get the latest articles, simpy go to the bottom box of the right column, enter your email address and click on “Follow.”
Deep Brain Stimulation
Below you’ll find a compilation of EFA summer camps and those supported by other organizations.
Ages range from 6 – 26, depending upon the camp and its activities.
Applications for this year’s summer camps are beginning. (Or starting very soon.) Dates and ages vary, depending upon the camp. So, it’s best you get the necessary info now, to avoid disappointment.
Camps should be contacted early for dates and applications.
Below is a compilation by website forum members who have had positive personal experiences with docs over the years…
Here are the facts, unhappy though they may be…
Epilepsy is the fourth most common neurological disorder in the U.S. after migraine, stroke, and Alzheimer’s disease. Its prevalence is greater than autism spectrum disorder, cerebral palsy, multiple sclerosis and Parkinson’s disease combined.
More people die from epilepsy than from breast cancer.
There are 200,000 new cases of epilepsy each year, and a total of more than 3 million Americans are affected by it.
Yet, public and private funding for epilepsy research lags far behind other neurological afflictions, at $35 a patient (compared, for instance, with $129 for Alzheimer’s and $280 for multiple sclerosis).
“It’s as if I’ve miniaturized my body and gone inside the patient.”
A science break-through: Robotic neurosurgery
This minimally invasive surgery avoids traditional drilling through the skull by using miniaturized surgical instruments that fit through a series of tiny incisions.
They are mounted on three separate robotic arms — allowing the surgeon maximum range of motion and precision and less trauma to the patient.
They’re necessary, but not necessarily nice. And every med has its own side-effects. Just as different people experience different difficulties. Here‘s the low-down on the possible side-effects of your drugs and others. Some might sound painfully familiar…
If you’ve been blessed with reasonably good health, you probably don’t have a surgeon’s number on speed dial. Therefore, the bigger question is, in the unfortunate event that you need one, how do you find the best surgeon for your medical condition?
Long before Dilantin and Phenobarbital, there was epilepsy. And herbal remedies.
Of course, these herbal epilepsy remedies are NOT substitutes to anti-seizure medications, but are more like a supplementary support. Most of them work by preventing a seizure and other symptoms of epilepsy. (NYU Langone Medical Center estimates that 20 percent of people taking prescription drugs also use herbs.)